CM
BTAI icon

Caption Management’s BioXcel Therapeutics BTAI Stock Holding History

Caption Management’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,094
Closed -$649K – 1286
2023
Q2 		$649K Buy
6,094
+5,281
+650% +$1.76M 0.01% 762
2023
Q1 		$243K Buy
+813
New +$347K ﹤0.01% 900
2021
Q2 		– Sell
-2,500
Closed -$1.73M – 1315
2021
Q1 		$1.73M Buy
2,500
+990
+66% +$796K 0.04% 556
2020
Q4 		$1.11M Buy
1,510
+572
+61% +$446K 0.03% 581
2020
Q3 		$650K Buy
+938
New +$704K 0.02% 717

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caption Management's BTAI Position: Q3 2023 in Review

Caption Management sold out of BioXcel Therapeutics (BTAI) in Q3 2023, closing a stake of 6,094 shares — an estimated $649K sold.

Caption Management first reported a position in BTAI in Q3 2020 and held it in 5 quarters. The position peaked at $1.73M in Q1 2021. 85 funds tracked by Wall St. Rank hold BTAI as of Q3 2023.

  • Caption Management reported no remaining BioXcel Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Caption Management sold 6,094 BioXcel Therapeutics shares in Q3 2023, an estimated $649K.
  • Caption Management first reported a position in BioXcel Therapeutics in Q3 2020 and held it in 5 quarters.
  • Caption Management's BioXcel Therapeutics position peaked at $1.73M in Q1 2021.
  • 85 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2023.

Based on Caption Management's 13F filing for Q3 2023, filed 14 Nov 2023.